Compare TOUR & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOUR | SCLX |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | China | United States |
| Employees | N/A | 34 |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.6M | 55.1M |
| IPO Year | 2014 | N/A |
| Metric | TOUR | SCLX |
|---|---|---|
| Price | $5.10 | $6.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.4K | ★ 106.3K |
| Earning Date | 06-11-2026 | 04-10-2026 |
| Dividend Yield | ★ 17.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.30 | $122.52 |
| Revenue Next Year | $14.00 | $186.30 |
| P/E Ratio | $87.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $4.20 |
| 52 Week High | $7.79 | $34.27 |
| Indicator | TOUR | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 41.02 |
| Support Level | $0.66 | $5.72 |
| Resistance Level | $5.28 | $7.77 |
| Average True Range (ATR) | 0.13 | 1.02 |
| MACD | 0.05 | -0.26 |
| Stochastic Oscillator | 57.14 | 4.02 |
Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. The company offers a large selection of packaged tours, including organized tours and self-guided tours, and travel-related services for leisure travellers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.